Rintatolimod (Ampligen) combined with durvalumab (Imfinzi) has continued to exhibit encouraging efficacy, safety, and ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at nearly 3 years, according ...

Although patients who received tumor-infiltrating lymphocyte (TIL) therapy had favorable overall survival (OS), a significant number who were evaluated to receive lifileucel (Amtagvi) did not get ...

Although not as essential as in other tumor types, genomic testing is increasingly playing a role in guiding treatment for advanced sarcoma.

The FDA has approved a label update for axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed autologous T-cell immunotherapy. This update removes previous Limitations of Use for patients with ...

EB103 utilizes Eureka’s ARTEMIS technology, a platform designed to harness the human immune system more effectively than standard therapies. The ARTEMIS T cells are engineered to address the specific ...

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

Community oncology plays a central role in the US health care system, offering high-quality care that is both accessible and ...

The FDA has granted priority review to the supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) ...

t-MDS treatments boost remission with HMA combinations, yet overall survival still lags; experts await breakthrough therapies ...

The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...

In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, GI medical oncologist at Baptist Health Miami Cancer ...